Impact of the COVID-19 pandemic on the Internet latency: A large-scale study

The COVID-19 pandemic dramatically changed the way of living of billions of people in a very short time frame. In this paper, we evaluate the impact on the Internet latency caused by the increased amount of human activities that are carried out on-line. The study focuses on Italy, which experienced significant restrictions imposed by local authorities, but results about Spain, France, Germany, Sweden, and the whole of Europe are also included. The analysis of a large set of measurements shows that the impact on the network can be significant, especially in terms of increased variability of latency. In Italy we observed that the standard deviation of the average additional delay – the additional time with respect to the minimum delay of the paths in the region – during lockdown is ∼3−4 times as much as the value before the pandemic. Similarly, in Italy, packet loss is ∼2−3 times as much as before the pandemic. The impact is not negligible also for the other countries and for the whole of Europe, but with different levels and distinct patterns

MECPerf: An Application-Level Tool for Estimating the Network Performance in Edge Computing Environments

Edge computing is an emerging architecture in 5G networks where computing power is provided at the edge of the fixed network, to be as close as possible to the end users. Computation offloading, better communication latency, and reduction of traffic in the core network are just some of the possible benefits. However, the Quality of Experience (QoE) depends significantly on the network performance of the user device towards the edge server vs. cloud server, which is not known a priori and may generally change very fast, especially in heterogeneous, dense, and mobile deployments. Building on the emergence of standard interfaces for the installation and operation of thirdparty edge applications in a mobile network, such as the MultiAccess Edge Computing (MEC) under standardization at the European Telecommunications Standards Institute (ETSI), we propose MECPerf, a tool for user-driven network performance measurements. Bandwidth and latency on different network segments are measured and stored in a central repository, from where they can be analyzed, e.g., by application and service providers without access to the underlying network management services, for run-time resource optimization

Steric control in the metal-ligand electron transfer of iminopyridine-ytterbocene complexes

International audienceA systematic study of reactions between Cp*Yb-2(THF) (Cp* = eta(5)-C5Me5, 1) and iminopyridine ligands (IPy = 2,6-(Pr2C6H3N)-Pr-i=CH(C5H3N-R), R = H (2a), 6-C4H3O (2b), 6-C4H3S (2c), 6-C6H5 (2d)) featuring similar electron accepting properties but variable denticity and steric demand, has provided a new example of steric control on the redox chemistry of ytterbocenes. The reaction of the unsubstituted IPy 2a with 1, either in THF or toluene, gives rise to the paramagnetic species Cp*Yb-2(III)(IPy)(center dot-) (3a) as a result of a formal one-electron oxidation of the Yb-II ion along with IPy reduction to a radical-anionic state. The reactions of 1 with substituted iminopyridines 2b-d, bearing aryl or hetero-aryl dangling arms on the 6 position of the pyridine ring occur in a non-coordinating solvent (toluene) only and afford coordination compounds of a formally divalent ytterbium ion, coordinated by neutral IPy ligands Cp*Yb-2(II)(IPy)(0) (3b-d). The X-ray diffraction studies revealed that 2a-c act as bidentate ligands; while the radical-anionic IPy in 3a chelates the Yb-III ion with both nitrogens, neutral IPy ligands in 3b and 3c participate in the metal coordination sphere through the pyridine nitrogen and O or S atoms from the furan or thiophene moieties, respectively. Finally, in complex 3d the neutral IPy ligand formally adopts a monodentate coordination mode. However, an agostic interaction between the Yb-II ion and an ortho C-H bond of the phenyl ring has been detected. Imino-nitrogens in 3b-d are not involved in the metal coordination. Variable temperature magnetic measurements on 3a are consistent with a multiconfigurational ground state of the Yb ion and suggest that the largest contribution arises from the 4f(13)-radical configuration. For complexes 3b and 3c the data of magnetic measurements are indicative of a Yb-II-closed shell ligand electronic distribution. Complex 3d is characterized by a complex magnetic behavior which does not allow for an unambiguous estimation of its electronic structure. The results are rationalized using DFT and CSSCF calculations. Unlike diazabutadiene analogues, 3a does not undergo a solvent mediated metalligand electron transfer and remains paramagnetic in THF solution. On the other hand, complexes 3b-d readily react with THF to afford 1 and free IPy 2b-d

A multicenter epidemiological study on second malignancy in non-syndromic pheochromocytoma/paraganglioma patients in Italy

SIMPLE SUMMARY: As no previous studies had assessed the risk of second malignant tumors in patients with pheochromocytomas/paragangliomas (PPGLs), we aimed to evaluate whether these patients could have an increased risk of additional malignancy, comparing them with patients in the general population who had a first malignancy and developed a second malignant tumor. We demonstrated that PPGL patients had higher incidence of additional malignant tumors and the risk of developing a second malignant tumor increased with age at diagnosis. As the main tumors were prostate, colorectal and lung/bronchial cancers in males, and breast cancer, differentiated thyroid cancer and melanoma in females, our findings could have an impact on the surveillance strategy. ABSTRACT: No studies have carried out an extensive analysis of the possible association between non-syndromic pheochromocytomas and paragangliomas (PPGLs) and other malignancies. To assess >the risk of additional malignancy in PPGL, we retrospectively evaluated 741 patients with PPGLs followed-up in twelve referral centers in Italy. Incidence of second malignant tumors was compared between this cohort and Italian patients with two subsequent malignancies. Among our patients, 95 (12.8%) developed a second malignant tumor, which were mainly prostate, colorectal and lung/bronchial cancers in males, breast cancer, differentiated thyroid cancer and melanoma in females. The standardized incidence ratio was 9.59 (95% CI 5.46–15.71) in males and 13.21 (95% CI 7.52–21.63) in females. At multivariable analysis, the risk of developing a second malignant tumor increased with age at diagnosis (HR 2.50, 95% CI 1.15–5.44, p = 0.021 for 50–59 vs. 60- vs. <50-year). In patients with available genetic evaluation, a positive genetic test was inversely associated with the risk of developing a second tumor (HR 0.25, 95% CI 0.10–0.63, p = 0.003). In conclusion, PPGLs patients have higher incidence of additional malignant tumors compared to the general population who had a first malignancy, which could have an impact on the surveillance strategy

An Epididymis-Specific Secretory Protein HongrES1 Critically Regulates Sperm Capacitation and Male Fertility

Mammalian sperm capacitation is an essential prerequisite to fertilizion. Although progress had been made in understanding the physiology and biochemistry of capacitation, little is known about the potential roles of epididymal proteins during this process. Here we report that HongrES1, a new member of the SERPIN (serine proteinase inhibitor) family exclusively expressed in the rat cauda epididymis and up-regulated by androgen, is secreted into the lumen and covers the sperm head. Co-culture of caudal sperms with HongrES1 antibody in vitro resulted in a significant increase in the percentage of capacitated spermatozoa. Furthermore, the percentage of capacitated spermatozoa clearly increased in rats when HongrES1 was down-regulated by RNAi in vivo. Remarkably, knockdown of HongrES1 in vivo led to reduced fertility accompanied with deformed appearance of fetuses and pups. These results identify HongrES1 as a novel and critical molecule in the regulation of sperm capacitation and male fertility

Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study

BACKGROUND: Adjuvant treatment with mitotane is commonly used after resection of adrenocortical carcinoma; however, treatment remains controversial, particularly if risk of recurrence is not high. We aimed to assess the efficacy and safety of adjuvant mitotane compared with surveillance alone following complete tumour resection in patients with adrenocortical carcinoma considered to be at low to intermediate risk of recurrence. METHODS: ADIUVO was a multicentre, open-label, parallel, randomised, phase 3 trial done in 23 centres across seven countries. Patients aged 18 years or older with adrenocortical carcinoma and low to intermediate risk of recurrence (R0, stage I-III, and Ki67 ≤10%) were randomly assigned to adjuvant oral mitotane two or three times daily (the dose was adjusted by the local investigator with the target of reaching and maintaining plasma mitotane concentrations of 14-20 mg/L) for 2 years or surveillance alone. All consecutive patients at 14 study centres fulfilling the eligibility criteria of the ADIUVO trial who refused randomisation and agreed on data collection via the European Network for the Study of Adrenal Tumors adrenocortical carcinoma registry were included prospectively in the ADIUVO Observational study. The primary endpoint was recurrence-free survival, defined as the time from randomisation to the first radiological evidence of recurrence or death from any cause (whichever occurred first), assessed in all randomly assigned patients by intention to treat. Overall survival, defined as time from the date of randomisation to the date of death from any cause, was a secondary endpoint analysed by intention to treat in all randomly assigned patients. Safety was assessed in all patients who adhered to the assigned regimen, which was defined by taking at least one tablet of mitotane in the mitotane group and no mitotane at all in the surveillance group. The ADIUVO trial is registered with ClinicalTrials.gov, NCT00777244, and is now complete. FINDINGS: Between Oct 23, 2008, and Dec 27, 2018, 45 patients were randomly assigned to mitotane and 46 to surveillance alone. Because the study was discontinued prematurely, 5-year recurrence-free and overall survival are reported instead of recurrence-free and overall survival as defined in the protocol. 5-year recurrence-free survival was 79% (95% CI 67-94) in the mitotane group and 75% (63-90) in the surveillance group (hazard ratio 0·74 [95% CI 0·30-1·85]). Two people in the mitotane group and five people in the surveillance group died, and 5-year overall survival was not significantly different (95% [95% CI 89-100] in the mitotane group and 86% [74-100] in the surveillance group). All 42 patients who received mitotane had adverse events, and eight (19%) discontinued treatment. There were no grade 4 adverse events or treatment-related deaths. INTERPRETATION: Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment. FUNDING: AIFA, ENSAT Cancer Health F2-2010-259735 programme, Deutsche Forschungsgemeinschaft, Cancer Research UK, and the French Ministry of Health

Estradiol inhibits the effects of extracellular ATP in human sperm by a non genomic mechanism of action

Steroid hormones, beside their classical genomic mechanism of action, exert rapid, non genomic effects in different cell types. These effects are mediated by still poorly characterized plasma membrane receptors that appear to be distinct from the classic intracellular receptors. In the present study we evaluated the non genomic effects of estradiol (17βE2) in human sperm and its effects on sperm stimulation by extracellular ATP, a potent activator of sperm acrosome reaction. In human sperm 17βE2 induced a rapid increase of intracellular calcium (Ca2+) concentrations dependent on an influx of Ca2+ from the extracellular medium. The monitoring of the plasma membrane potential variations induced by 17βE2 showed that this steroid induces a rapid plasma membrane hyperpolarization that was dependent on the presence of Ca2+ in the extracellular medium since it was absent in Ca2+ free-medium. When sperm were pre-incubated in the presence of the K+ channel inhibitor tetra-ethylammonium, the 17βE2 induced plasma membrane hyperpolarization was blunted suggesting the involvement of K+ channels in the hyperpolarizing effects of 17βE2. Extracellular ATP induced a rapid plasma membrane depolarization followed by acrosome reaction. Sperm pre-incubation with 17βE2 inhibited the effects of extracellular ATP on sperm plasma membrane potential variations and acrosome reaction. The effects of 17βE2 were specific since its inactive steroisomer 17αE2 was inactive. Furthermore the effects of 17βE2 were not inhibited by tamoxifen, an antagonist of the classic 17βE2 intracellular receptor

ENSAT registry-based randomized clinical trials for adrenocortical carcinoma

Adrenocortical carcinoma (ACC) is an orphan disease lacking effective systemic treatment options. The low incidence of the disease and high cost of clinical trials are major obstacles in the search for improved treatment strategies. As a novel approach, registry-based clinical trials have been introduced in clinical research, so allowing for significant cost reduction, but without compromising scientific benefit. Herein, we describe how the European Network for the Study of Adrenal Tumours (ENSAT) could transform its current registry into one fit for a clinical trial infrastructure. The rationale to perform randomized registry-based trials in ACC is outlined including an analysis of relevant limitations and challenges. We summarize a survey on this concept among ENSAT members who expressed a strong interest in the concept and rated its scientific potential as high. Legal aspects, including ethical approval of registry-based randomization were identified as potential obstacles. Finally, we describe three potential randomized registry-based clinical trials in an adjuvant setting and for advanced disease with a high potential to be executed within the framework of an advanced ENSAT registry. Thus we, therefore, provide the basis for future registry-based trials for ACC patients. This could ultimately provide proof-of-principle of how to perform more effective randomized trials for an orphan disease